Vera Therapeutics Inc - Class A

NEW
NAS:VERA (USA)   Class A
$ 26.52 +0.61 (+2.35%) 12:08 AM EST
At Loss
P/B:
2.92
Market Cap:
$ 1.69B
Enterprise V:
$ 1.07B
Volume:
773.27K
Avg Vol (2M):
889.28K
Warning! GuruFocus detected 2 Severe warning signs with VERA. Try a 7-Day Free Trial to check it out.
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
773.27K
Market Cap $:
1.69B
At Loss
Avg Vol (2M):
889.28K
Enterprise Value $:
1.07B
PB Ratio:
2.92
Website SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocks™

Business Description

Vera Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US92337R1014
https://www.veratx.com
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005

Share Class Description:

VERA: Class A
Compare
Compare
TARSIOVAIRONBCRXIDYAWVETVTXAPGEHRMYNAMSVRTXASX:CSLREGNXKRX:207940XBRU:ARGXXBRU:UCBALNYONCBNTXXKRX:068270
Traded in other countries / regions
VERA.USA
Index Membership
Russell 2000Russell 3000
IPO Date
2021-05-14
Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Financial Strength

8/10
Name Current Vs Industry Vs History
Cash-To-Debt 11.73
Equity-to-Asset 0.88
Debt-to-Equity 0.1
Debt-to-EBITDA -0.38
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -2.7
3-Year EPS without NRI Growth Rate -2.8
3-Year FCF Growth Rate -11.6
3-Year Book Growth Rate 40.5
Future 3-5Y EPS without NRI Growth Rate Estimate 11.06

Momentum Rank

4/10
Name Current Vs Industry Vs History
5-Day RSI 36.52
9-Day RSI 36.13
14-Day RSI 36.32
3-1 Month Momentum % -28.98
6-1 Month Momentum % -32.3
12-1 Month Momentum % -32.9

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 25.67
Quick Ratio 25.67
Cash Ratio 25.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -44
Shareholder Yield % -38.47

Profitability Rank

1/10
Name Current Vs Industry Vs History
ROE % -46.12
ROA % -37.73
ROIC % -2928.25
3-Year ROIIC % -3046.54
ROC (Joel Greenblatt) % -4444.37
ROCE % -37.85

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 2.92
Price-to-Tangible-Book 2.92
EV-to-EBIT -7.37
EV-to-Forward-EBIT -20.09
EV-to-EBITDA -7.45
EV-to-FCF -7.91
Price-to-Net-Current-Asset-Value 2.94
Price-to-Net-Cash 3
Earnings Yield (Greenblatt) % -13.57
FCF Yield % -7.97

Financials

VERA's 30-Y Financials
AAPL
Income Statement Breakdown FY
Not Enough Data
AAPL
Balance Sheet Breakdown
Not Enough Data
AAPL
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:VERA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Vera Therapeutics Inc Executives

Details

GF Value

VERA

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.75
Beta 1.6
3-Year Sharpe Ratio 0.47
3-Year Sortino Ratio 1.11
Volatility % 43.5
14-Day RSI 36.32
14-Day ATR ($) 1.482401
20-Day SMA ($) 27.9715
12-1 Month Momentum % -32.9
52-Week Range ($) 25.55 - 51.61
Shares Outstanding (Mil) 63.75

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vera Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Vera Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Vera Therapeutics Inc Frequently Asked Questions

What is Vera Therapeutics Inc(VERA)'s stock price today?
The current price of VERA is $26.52. The 52 week high of VERA is $51.61 and 52 week low is $25.55.
When is next earnings date of Vera Therapeutics Inc(VERA)?
The next earnings date of Vera Therapeutics Inc(VERA) is .
Does Vera Therapeutics Inc(VERA) pay dividends? If so, how much?
Vera Therapeutics Inc(VERA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.